If this winds up being the case, Viking's differentiated obesity treatment could put it on a fast track to gain market share ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Despite signs that Viking's anti-obesity candidate could be a top seller in its category, the stock fell when the market ...

Morgan Stanley analyst Stephen Grambling upgraded Viking Holdings (VIK) to Overweight from Equal Weight with a price target of $49, up from ...

Should you take advantage of this opportunity and buy Viking on the dip? Let's find out. Read More: Earn up to $845 cash back ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...